Hemorheological Alterations in Patients with Heart Failure with Reduced Ejection Fraction Treated by Resveratrol

Table 2

Effect of resveratrol on hemorheological parameters.

	Baseline			3^rd month
	Control	Resveratrol	Placebo	Resveratrol	Placebo
Hematocrit (%)
WBV (mPas)		^#	^#
PV (mPas)
RBC aggregation (Myrenne)
RBC aggregation (LORCA)
AI		^#	^#
(s)		^#	^#
(1/s)		^#	^#

Values are expressed as . ^#Significant difference in the resveratrol or placebo groups compared to the control group at baseline; significant difference in 3^rd month values of the resveratrol group compared to the baseline values of the resveratrol group (). Baseline: measured values at randomization in the resveratrol group or in the placebo group; 3^rd month: patients treated with resveratrol or placebo for 3 months; AI: aggregation index; (s): aggregation half time; and values: aggregation indices at different rotation speeds of the aggregometer; PV: plasma viscosity; RBC: red blood cell; WBV: whole blood viscosity; (1/s): threshold shear rate.